(IN BRIEF) Basilea Pharmaceutica has partnered with INCATE, the European incubator for antibacterial therapies, to support the advancement of early-stage anti-infective innovations. As an industry partner, Basilea brings deep expertise in antibacterial and antifungal drug development, while expanding INCATE’s scope … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Non Profit, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged anti-infectives, antibacterial therapies, antifungal therapies, antimicrobial resistance, Basel life sciences, Basilea Joins INCATE to Advance Early-Stage Antibacterial and Antifungal Innovation in Europe, Basilea Pharmaceutica, biopharmaceutical innovation, clinical development, drug development, INCATE, industry partnership, infectious diseases, invasive fungal infections, Laurenz Kellenberger, preclinical research, Primo Schär, University of Basel
(IN BRIEF) Basilea Pharmaceutica has entered into a strategic collaboration with Prokaryotics to develop a first-in-class broad-spectrum antifungal therapy targeting severe invasive fungal infections. The partnership focuses on novel compounds with a new mode of action aimed at pathogens such … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Switzerland, Technology
Tagged anti-infective research, antifungal drug development, Aspergillus, Basilea Partners with Prokaryotics to Develop Novel Broad-Spectrum Antifungal Therapy, Basilea Pharmaceutica, biopharmaceutical collaboration, Candida, clinical development, first in class antifungal, global licensing agreement, invasive fungal infections, Laurenz Kellenberger, novel mode of action, Prokaryotics, rare molds, Terry Roemer
(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AKP, antifungal treatment, Asahi Kasei Pharma, aspergillosis, azole antifungal, Basilea Pharmaceutica, biopharmaceuticals, branded antifungal leader, Cresemba®, cryptococcosis, David Veitch, fungal infection therapies, global antifungal sales, intravenous antifungal, invasive fungal infections, Isavuconazole, Japan pharmaceutical market, Japanese drug market, milestone payment, mucormycosis, oral antifungal, partnership
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?